Log in to our secure, personalized website to manage your care (formerly myMDAnderson).
If you are ready to make an appointment, select a button on the right. If you have questions about MD Anderson’s appointment process, our information page may be the best place to start.
Appointment InformationRESEARCH PLATFORM FOR
THE MOON SHOTS PROGRAM
Biologic therapeutics, such as monoclonal antibodies and cell therapies, have revolutionized cancer treatment. The Biologics Development team is pioneering efforts in this field to bring innovative new treatment options for patients in need.
Biologics Development is part of MD Anderson’s Therapeutics Discovery division, a unique group of clinicians, researchers and drug development experts working in tandem to develop the next generation of impactful cancer medicines.
Biologics Development works closely with leading MD Anderson clinicians and researchers to help define the leading edge of biologics therapies and rapidly advance products to patients and clinical proof-of-concept. The platform also engages in strategic industry collaborations to co-develop innovative products, rapidly utilizing the expansive MD Anderson ecosystem.
MD Anderson’s state-of-the-art Cell Therapy Manufacturing Facility provides industrial drug-development expertise to advance cell therapy programs from laboratory concepts to commercializable therapeutics. Acquired in 2020, the good manufacturing practice (GMP) facility is located just blocks from the Texas Medical Center campus, making it an ideal facility to bring together the world-class research and unmatched clinical care that MD Anderson has to offer.
The Cell Therapy Manufacturing Facility is managed by the Biologics Development team and led by an experienced biopharmaceutical team with a combined 150 years of industry experience. The staff of industry veterans and MD Anderson scientists creates a unique culture of innovation and industrial good manufacturing practices (GMPs) with expertise in chimeric antigen receptor (CAR) T-cell therapy, tumor-infiltrating lymphocyte (TIL) therapy, endogenous T-cell (ETC) therapy as well as other emerging and enabling cell-therapy modalities. The GMP facility boasts 11 clean rooms, 30,000 square feet of BSL-2+ clean rooms and support laboratory space for Proof of Concept trials, pivotal trials and commercial launch, as needed. Additionally, three GMP clean rooms are located on a separate floor and serve as an ideal venue for viral vector manufacturing.
Jason Bock, Ph.D., vice president of Therapeutics Discovery and head of Biologics Development, speaks to Cancerwise about tumor-infiltrating lymphocytes (TILs) and how this experimental cell therapy is being developed to treat solid tumors.
Learn moreMD Anderson and Refuge Biotechnologies announced a strategic
collaboration to advance new cell therapies for potential treatment of
solid tumors. The agreement pairs Refuge’s innovative technologies
with the experience and industrial capability of the Biologics
Development platform.
Advancing cell therapy development
With recent agreements, the Biologics Development team has expanded MD Anderson’s manufacturing and research capacity for cell therapies. The new facility provides industrial capacity and expertise to accelerate MD Anderson’s cell therapy efforts toward meaningful clinical advances.
MD Anderson and Obsidian Therapeutics announced a multi-year strategic collaboration to expedite the research and development of novel engineered tumor-infiltrating lymphocytes (TILs) for the treatment of solid tumors. The agreement pairs Obsidian’s novel technology platform with MD Anderson’s extensive experience and capabilities, led by the Biologics Development platform.
